Proscia’s Concentriq for Research is an example of an advanced digital pathology platform.
As drug discovery evolves, digital pathology platforms are playing a vital role in streamlining preclinical R&D processes and accelerating drug discovery. Proscia‘s Concentriq for Research reflects this trend.
Earlier this year, we profiled PathAI’s AISight, a digital pathology platform designed to support AI-driven research. To learn more about Proscia’s digital pathology technology, we caught up with Nathan Buchbinder, co-founder and chief product officer at Proscia, who discussed how the Concentriq for Research digital pathology platform streamlines the preclinical R&D process and accelerates studies. In the following Q&A, he highlights the benefits of Good Laboratory Practice (GLP) compliance, the role of AI in unlocking new insights and how the platform facilitates collaboration…